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Abstract 
We estimated the inpatient resource use for a Fontan patient from birth to adulthood and 
explored factors that might induce cost differences (2014 US dollar). Inpatient costing 
records from four hospitals with greatest numbers of Fontan patients in Australia and New 
Zealand were linked with the Fontan registry database. Inpatient records between July 1995 
and September 2014 for 420 Fontan patients were linked, and the most frequent primary 
diagnoses were hypoplastic left heart syndrome (HLHS) (20.7%), tricuspid atresia (19.7%), 
and double inlet left ventricle (17.1%). The mean hospital cost for a Fontan patient from birth 
to 18 years of age was estimated to be $390,601 (95% confidence interval [CI] $264,703 to 
$516,499), corresponding to 164 (95% CI 98 to 231) inpatient days. The cost incurred from 
birth through to Fontan completion (the staged procedures period) was $219,482 (95% CI 
$202,410 to $236,553) and the cost thereafter over 15 years was $146,820 (95% CI $44,409 
to $249,231), corresponding to 82 (95% CI 72 to 92) and 65 (95% CI 18 to 112) inpatient 
days respectively. Costs were higher in male and HLHS patients in the staged procedures 
period (P<0.001). Having fenestration was associated with higher costs in the staged 
procedures period (P<0.001) and lower cost post Fontan over 15 years (P=0.66). In 
conclusion, patients with single-ventricle congenital heart disease continue to demand 
considerable inpatient resources after the staged procedures period. Over 40% of the pediatric 
hospital costs for Fontan patients were estimated to occur after the last planned surgery.  
Key Words: Fontan patients, hospital cost, congenital heart disease, health service 
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The Fontan procedure is the final in a series of staged palliations for single-ventricle 
congenital heart disease, affecting approximately 1 in 2000 live births.1, 2 As the outcomes of 
the staged procedures improve, an increasing number of children with complex heart 
conditions have survived into adulthood.2-5 More patients are now undergoing staged 
procedures6-8 but the trend in long-term inpatient cost and care needs for this population are 
unclear. Using hospital billing data associated with encounters, Keren et al. (2012) have 
shown that the cumulative costs of the 10 most expensive pediatric conditions in the US 
accounted for approximately one third of the standardized costs for all pediatric visits to 
hospital, and single-ventricle congenital heart defects such as hypoplastic left heart syndrome 
(HLHS) ranked 7th on the list.9 Previous studies also documented the costs of a single staged 
procedure10, 11, the costs of non-cardiac admissions to pediatric hospitals12, and the costs of 
admissions in adults for this patient group.13 Nevertheless, the literature is limited by its focus 
on single encounters and knowledge regarding the long-term trend in hospital costs  for 
single-ventricle patients is lacking. The purpose of this study was to assess the trend in long-
term hospital costs for single-ventricle patients surviving the Fontan procedure throughout 
childhood and adolescence to inform the planning of inpatient resources and predicting and 
budgeting for the needs of the Fontan population as it grows over time. 
Methods 
The Australia and New Zealand Fontan registry is a population-based registry of Fontan 
patients in this binational region with 1,395 patients enrolled at the commencement of this 
study. The Fontan procedures in the registry database are strictly defined as atriopulmonary 
connection, lateral tunnel modification or extracardiac conduit, and only patients who 
underwent the Fontan procedure are included in the registry. Details about the Australia and 
New Zealand Fontan registry and the data inclusion criteria have been previously described.2 
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Information extracted from the registry for this study were patient demographics, cardiac 
morphology, presence of fenestration, date of Fontan, and Fontan site.  
From the registry database, four hospitals were identified as the Fontan sites for 1,196 
patients– the majority of the Fontan patients in the region from June 1975 to June 2015. 
Three of the hospitals are in Australia (The Mater Children’s Hospital, The Children's 
Hospital at Westmead, and The Royal Children's Hospital) and one in New Zealand (The 
Starship Children’s Hospital). In accordance with the ethical approval obtained for the 
registry, hospital admission records for the registry-enrolled patients were requested from 
the administrative databases. Inpatient records between July 1995 and September 2014 
were received with hospitals providing varying lengths of costing data depending on local 
hospital archiving policies. Information available from the administrative records are 
patient’s identifier, admission and discharge date, episode-related Australian Refined 
Diagnosis Related Groups (AR-DRG) code and the episode’s total cost, where AR-DRG 
classification categorizes episodes of care into those with similar conditions and similar 
usage of hospital resources using information in the hospital record such as the diagnoses, 
procedures and demographic characteristics of the patient. Various stages of hospital care 
for a Fontan patient were covered in the window of data capture, depending on patient’s 
date of birth, time of death and the length of the inpatient records available.  
To link the registry data with the hospital administrative records, a combination of 
patient identifier, first name and last name were used. To adjust for the differences 
between currencies and timing of valuations, inpatient costs incurred prior to 2014 in New 
Zealand were inflated to 2014 New Zealand dollars using the annual Consumer Price 
Index published by the Reserve Bank of New Zealand. Costs incurred in Australia prior to 
2014 were inflated to the 2014 price using the state-specific health Consumer Price Index 
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published by the Australian Bureau of Statistics. Costs were then converted to US dollar 
using the average annual rate of exchange published by the Federal Reserve. All costs are 
presented in 2014 US dollars ($). 
To estimate the hospital costs for an average Fontan patient, all episode costs, both cardiac 
and non-cardiac related, were included. The rationale for including all episode costs is to 
capture the total long-term inpatient cost for a Fontan patient, taking account of the costs for 
the staged operations, any preoperative and postoperative complications and other health 
conditions, as children with complex chronic conditions often use more inpatient resources 
for reasons unrelated to the cause of admission.9 To demonstrate the reasons of hospital 
resources utilized, the most common episode-related AR-DRG codes were summarized. 
Average total hospital cost from birth to 18 years of age was estimated by assigning 
episode costs to a patient’s age at hospital discharge so that an annual cost associated with 
each year of age can be calculated. Costs for the years where no hospital records were present 
between episodes for individual patients were set to be zero. Costs for the periods outside the 
first and last observable episodes were set to be missing. Average length of stay for each year 
of age was also calculated, and same-day admission was estimated as one inpatient day for 
simplicity. 
Hospital costs were further distingusihed for the staged modifications period which is 
identified as the period from birth through to the completion of the Fontan procedure (staged 
procedures period), and post Fontan over 15 years (post-Fontan period). The two periods 
were divided using the discharge date of the Fontan procedure plus 90 days as a convention 
to capture the inpatient stays for the staged modifications as well as the associated 
complications. In the staged procedures period, only the costs of patients who had inpatient 
records available from the birth year through to Fontan completion were used so that major 
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cost components such as the staged operations are covered, minimizing the potential bias 
from failing to observe significant costs. In the post-Fontan period, episode costs were 
assigned to each year since the completion of the Fontan procedure– similar to the method 
employed to estimate costs by age as described previously– and the average annual costs 
were summed over 15 years as the total average cost for the period. Patients with various 
lengths of cost data available in this period were included without censoring as little is 
known from the literature to advice key cost drivers and inform censoring.  
Costs incurred in the two periods were also grouped by cardiac, non-cardiac or non-
specific reasons based on the major diagnostic category descriptions published by the 
Department of Health for AR-DRG version 6.0. More specifically, cardiac costs include 
costs for diseases and disorders of the circulatory system coded in the range of F01Z to 
F75C along with heart transplant procedures and cardiac procedures for neonates. Non-
specific costs include costs incurred for surgical follow-ups and other contacts with health 
services coded in the range of Z61A to Z65Z along with neonate procedures described as 
admissions with multiple major problems. All other costs that are distinctly not cardiac are 
grouped as non-cardiac costs. Historical cost data that related to older versions of AR-
DRG were mapped to AR-DRG version 6.0 based on the major diagnostic category 
descriptions unless stated otherwise.  
To further investigate variation in cost, we examined the mean cost differences by 
gender, primary diagnosis being HLHS, and fenestration status in the staged procedures 
period and post-Fontan period (subgroup analysis) using 1,000 random draws from the 
bootstrapped cost distributions of the subgroups. Analyses were performed with the Stata 
statistical software package (version 14.0, Texas, USA). 
Results  
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At the completion of the linking process, patients were de-identified and 3,175 inpatient 
records for 420 patients were obtained. The characteristics of the 420 patients in the linked 
dataset are summarized in Table 1 and compared with all patients in the registry who were 
born in the same period (after year 1995). There were no statistically significant differences 
between the two samples.  
Table 2 summarizes the most common AR-DRG diagnostic codes for Fontan patients in 
the linked dataset to demonstrate the most frequent reasons for hospital admission. It is 
evident from Table 2 that whilst cardiac hospital admissions are prominent, non-cardiac 
inpatient care such as dental extractions and restorations and treatment for digestive system 
disorders were also frequently used by Fontan patients. 
Average inpatient hospital costs and length of stay for each year of age are presented in 
Figure 1. The average total hospital cost for a Fontan patient from birth to 18 years of age 
was estimated to be $390,601 (95% Confidence Interval [CI] $264,703 to $516,499), 
corresponding to 164 (95% CI 98 to 231) inpatient days. Patients required a significant 
amount of inpatient resources in the first year of life, with the mean cost estimated to be 
$134,885 (95% CI $120,595 to $149,175). The primary contributor to this high average 
resource use is the staged modifications prior to Fontan, typically the Norwood and the 
bidirectional cavo-pulmonary shunt procedure.11, 14 The second peak of the average hospital 
cost was observed between 5 to 7 years of age, at the time of the Fontan procedure. Moving 
from 15 years of age onwards, average hospital costs grew slightly and the estimated 
confidence intervals grew wider, reflecting smaller numbers of patients observed and higher 
variation in cost as patients approach adulthood. 
Furthermore, the total hospital costs in the staged procedures period and post-Fontan over 
15 years were estimated along with the percentage contributions of cardiac, non-cardiac and 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
non-specific inpatient care in each period (Figure 2). Cardiac costs appeared to dominate 
in both periods. Although the contribution of non-cardiac admissions was small in the 
staged procedures period (4%), it was estimated to take a much bigger share of the total 
cost in the post-Fontan period (20%). 
Table 3 presented the results of the subgroup analysis. It was estimated that being male 
and being diagnosed with HLHS were associated with higher average costs in the staged 
procedures period compared to being female and being diagnosed with other single-
ventricle heart diseases (P<0.001). Compared to patients without fenestration, patients 
with fenestration had a higher average cost for the staged procedures period (P<0.001) and 
a slightly lower average cost afterwards (P=0.66). 
Discussion 
Using data from the hospitals in Australia and New Zealand and the Fontan registry, 
this study quantified the inpatient hospital costs for a Fontan patient from birth to 
adulthood. The findings confirm that the initial costs across the staged modifications 
period are most substantial for Fontan patients, and that the first year of life requires 
considerably more resources on average than any other years that follow. The overall cost 
of the staged procedures period was estimated to be $219,482 for an average Fontan 
patient, which aligned with the US literature where the average total cost of the three 
staged procedures was estimated to be $299,492 for HLHS patients.11 The average total 
cost incurred after the staged operations over a 15-year period is lower compared with the 
staged procedures period but still substantial. HLHS patients are estimated to require more 
resources on average as expected, and so are male children which is in line with the 
pediatric healthcare literature on gender15 and previous Fontan studies.16  
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We also found noticeable needs for non-cardiac hospital care with unexpected number of 
admissions related to treatments for digestive system disorders and dental extractions and 
restorations. These conditions are not currently recognized as one of the most common non-
cardiac inpatient needs for this population, although a few previous studies15-18 have reported 
worse dental caries experience and comorbidities in digestive system for children with heart 
disease. However, it is unclear from this study whether these admissions simply reflect more 
inpatient needs for this population on commonly seen conditions due to anesthesia concerns 
or that these children indeed had worse dental and digestive outcomes. More research may be 
helpful to confirm. Nevertheless, non-cardiac care appears to take a bigger share of the 
average total inpatient cost in the post-Fontan period and accounts for approximately 20% of 
the total cost. These inpatient needs should be taken into consideration in planning for the 
complete care of the Fontan population, particularly with more patients now surviving into 
adulthood. 
There are several limitations to this study. We assumed that Fontan patients’ hospital costs 
throughout childhood and adolescence can be represented by the costs incurred at their 
Fontan hospitals and costs for the years where no costing records were present between 
episodes were set to be zero. As children can attend other hospitals especially for non-cardiac 
care, this could lead to an underestimation of non-cardiac costs. Acknowledging this, our 
experience from the population-based Fontan registry suggests that majority of the hospital 
care for Fontan patients in Australia and New Zealand occurs in a reference hospital across 
childhood and adolescence due to the need for continuity of care because of their unique 
health condition. As a result, the potential bias is likely to be small. The cost estimations are 
more representative of patients who survived the Fontan procedure as patients who died 
before Fontan were not included in the Fontan registry, which could lead to the inpatient 
resource use being underestimated especially prior to Fontan. 
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Nevertheless, this study is the first that quantifies the long-term inpatient hospital costs 
for Fontan patients from birth to adulthood. Single-ventricle congenital heart disease is 
transforming from a fatal disease to a chronic condition, and the provision of hospital care 
for these patients does not stop after the last planned surgery. This study shows that 
approximately 40% of the pediatric hospital costs for this patient group occur after the last 
planned surgery. As the single-ventricle population are projected to double within the next 
twenty years5, the results provide relevant information for the planning of inpatient 
resources and predicting and budgeting for the needs of the Fontan population. 
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Figure lengends  
Figure 1. Average hospital cost and length of stay per patient from birth to 18 years of age. 
Figure 2. Cardiac, non-cardiac and non-specific hospital resource use in the staged 
procedures period and post-Fontan period. In the staged procedures period, 154 patients who 
have inpatient records from the birth year through to the completion of Fontan were included. 
In the post-Fontan period, inpatient records from 263 patients were used and the number of 
patients included for each year since Fontan ranges from 29 to 122. 
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Table 1 
Characteristics of patients in the linked dataset compared with the patients in the registry who were born 
after 1995 
Variable  Linked dataset, 
N=420 
Registry patients 
born after year 
1995, N=815 
P value 
Male 249/419 (59%) 482/815 (59%) 0.96 
Fenestrated 147/256 (57%) 199/399 (50%) 0.06 
Primary diagnosis 
 
  
    HLHS 86/416 (21%) 150/795 (19%) 0.45 
    Tricuspid atresia 82/416 (20%) 140/795 (18%) 0.37 
    Double inlet left ventricle 71/416 (17%) 111/795 (14%) 0.15 
    Double outlet right ventricle 43/416 (10%) 103/795 (13%) 0.18 
    Atrioventricular canal or atrioventricular septal defect  31/416 (7%) 66/795 (8%) 0.61 
    Congenitally corrected transposition of great arteries 30/416 (7%) 53/795 (7%) 0.72 
    Pulmonary atresia with intact ventricular septum 27/416 (6%) 70/795 (9%) 0.16 
    Pulmonary atresia with ventricular septal defect 6/416 (1%) 12/795 (2%) 0.93 
    Ebsteins anomaly 2/416 (0%) 8/795 (1%) 0.34 
    Other diagnoses 38/416(9%) 82/795 (10%) 0.51 
HLHS = Hypoplastic left heart syndrome. 
Note: denominators reflect data availability.  
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Table 2 
The diagnostic codes that were most frequent in the linked dataset (N=420) 
Reasons for inpatient resources use, AR-DRG description (AR-DRG code) Number of 
admissions 
Staged procedures period  
Cardiac reasons  
− Congenital Heart Disease with or without complication or comorbidity (F68A&F68B) 479 
− Other cardiothoracic/vascular procedures with CPB pump with or without catastrophic or severe or 
moderate complication or comorbidity (F07A&F07B&F07C) 
389 
− Circulatory disorders without AMI with invasive cardiac investigation procedures with or without 
catastrophic or severe complication or comorbidity, or sameday (F42A&F42B&F42C) 
300 
− Cardiothoracic/vascular procedures for neonates (P02Z) 38 
− Other cardiothoracic procedures without CPB pump with or without catastrophic or severe or 
moderate complication or comorbidity (F09A&F09B&F09C) 
31 
Non- cardiac reasons  
− Otitis media and upper respiratory infection (D63Z) 56 
− Oesophagitis and gastroenteritis with or without catastrophic or severe complication or comorbidity 
(G67A&G67B) 
36 
− Dental extractions and restorations (D40Z) 33 
Non-specific reasons  
− Neonate, admission weight >2499g with significant operating room procedures with or without 
multiple major problems (P06A&P06B) 
65 
− Other contacts with health services, sameday or not (Z64A&Z64B)  36 
− Tracheostomy with ventilation >95 hours  (A06A&A06B) 28 
Post-Fontan period  
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Cardiac reasons  
− Congenital Heart Disease with or without complication or comorbidity (F68A&F68B) 119 
− Circulatory disorders without AMI with invasive cardiac investigation procedures with or without 
catastrophic or severe complication or comorbidity, or sameday (F42A&F42B&F42C) 
96 
− Other circulatory system diagnoses with or without catastrophic or severe or moderate complication 
or comorbidity (F75A&F09B&F09C) 
44 
− Other cardiothoracic/vascular procedures with CPB pump with or without catastrophic or severe or 
moderate complication or comorbidity (F07A&F07B&F07C) 
28 
− Chest pain (F74Z) 25 
Non- cardiac reasons  
− Dental extractions and restorations (D40Z) 59 
− Other digestive system diagnoses with or without complication or comorbidity (G70A&G70B) 51 
− Oesophagitis and gastroenteritis with or without catastrophic or severe complication or comorbidity 
(G67A&G67B) 
36 
Non-specific reasons  
− Other contacts with health services, sameday or not (Z64A&Z64B)  66 
− Other respiratory system diagnosis with or without complication or comorbidity 
(E75A&E75B&E75C) 
21 
− Other Infectious and parasitic diseases with complication or comorbidity (T64A&T64B) 15 
    AMI = acute myocardial infarction; CPB = cardiopulmonary bypass. 
    Codes are consistent with AR-DRG version 6.0 unless otherwise noted. 
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Table 3 
Mean cost differences by gender, morphology, and fenestration in the staged procedures period and post-
Fontan period 
 
The staged procedures 
period 
P Post-Fontan period P 
  Male vs. Female  $36,151 <0.001 $29,720 =0.04 
  HLHS vs. All others $63,013 <0.001 –a 
  Fenestration vs. None $25,333 <0.001 -$7,432 =0.66 
    HLHS = Hypoplastic left heart syndrome. 
    
aMean cost cannot be compared due to small number of HLHS patients with cost data available in the 
years approaching the end of the defined post-Fontan period.  
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